BiotechTube
Draig Therapeutics

Draig Therapeutics

Cambridge, United Kingdom· Est.
draigtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $162.4M

Overview

Draig Therapeutics is a private, Cambridge-based biotech that emerged from stealth in mid-2025 with a substantial $140 million Series A financing to advance its pipeline of novel neuromodulators. The company is led by a seasoned team, including CEO Ivana Magovčević-Liebisch and Board Chair Douglas E. Williams, and is backed by a top-tier investor syndicate. With a clear focus on addressing the significant unmet need in neuropsychiatry, Draig's strategy centers on developing best-in-class modulators of glutamate and GABA receptors, aiming to deliver transformative treatments for conditions like MDD.

NeuropsychiatryMajor Depressive Disorder

Technology Platform

Platform for developing highly selective positive allosteric modulators (PAMs) of glutamate (AMPA) and GABA receptors to restore synaptic balance in neuropsychiatric disorders.

Funding History

4
Total raised:$162.4M
Venture$140M
Seed$3.2M
Series A$15M
Seed$4.2M

Opportunities

The massive, underserved global market for neuropsychiatric disorders, where current treatments fail many patients, presents a multi-billion dollar opportunity.
Successful clinical validation of Draig's novel glutamate and GABA modulators could position them as best-in-class, transformative therapies, attracting partnership interest from large pharma.

Risk Factors

High clinical development risk in the challenging neuropsychiatry field, with potential for trial failure due to complex biology and placebo effect.
Significant competition from other companies targeting similar glutamate and GABA pathways, some with more advanced programs.

Competitive Landscape

Draig operates in a competitive and active space targeting glutamate (AMPA, NMDA) and GABA receptors for neuropsychiatric indications. Competitors range from large pharma (e.g., Janssen with esketamine) to biotechs like Biohaven, Cerevel, and Sage Therapeutics. Differentiation will hinge on demonstrating superior efficacy, safety, and tolerability profiles.

More companies in Neuroscience & CNS →More companies in United Kingdom →